References
- Locati LD, Perrone F, Losa M, Mela M, Casieri P, Orsenigo M, Cortelazzi B, Negri T, Tamborini E, Quattrone P, et al. Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). Oral Oncol 2009; 45:986 - 90; http://dx.doi.org/10.1016/j.oraloncology.2009.05.635; PMID: 19574086
- Jaspers HC, Verbist BM, Schoffelen R, Mattijssen V, Slootweg PJ, van der Graaf WT, van Herpen CM. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol 2011; 29:e473 - 6; http://dx.doi.org/10.1200/JCO.2010.32.8351; PMID: 21422415
- Locati LD, Quattrone P, Bossi P, Marchianò AV, Cantù G, Licitra L. A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. Ann Oncol 2003; 14:1327 - 8; http://dx.doi.org/10.1093/annonc/mdg331; PMID: 12881399
- Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, et al, COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13:983 - 92; http://dx.doi.org/10.1016/S1470-2045(12)70379-0; PMID: 22995653
- Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, et al, COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368:138 - 48; http://dx.doi.org/10.1056/NEJMoa1209096; PMID: 23228172
- Kim S, Loevner L, Quon H, Sherman E, Weinstein G, Kilger A, Poptani H. Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res 2009; 15:986 - 94; http://dx.doi.org/10.1158/1078-0432.CCR-08-1287; PMID: 19188170
- Thoeny HC, Ross BD. Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging 2010; 32:2 - 16; http://dx.doi.org/10.1002/jmri.22167; PMID: 20575076
- Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 2003; 100:8424 - 9; http://dx.doi.org/10.1073/pnas.1431692100; PMID: 12826609
- Cros J, Sbidian E, Hans S, Roussel H, Scotte F, Tartour E, Brasnu D, Laurent-Puig P, Bruneval P, Blons H, et al. Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours. [Epub ahead of print] Ann Oncol 2013; 24:2624 - 9; http://dx.doi.org/10.1093/annonc/mdt338; PMID: 23933559
- Alimirah F, Panchanathan R, Chen J, Zhang X, Ho SM, Choubey D. Expression of androgen receptor is negatively regulated by p53. Neoplasia 2007; 9:1152 - 9; http://dx.doi.org/10.1593/neo.07769; PMID: 18084622
- Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 2009; 15:2472 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-08-1763; PMID: 19276248
- Williams MD, Roberts DB, Kies MS, Mao L, Weber RS, El-Naggar AK. Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res 2010; 16:2266 - 74; http://dx.doi.org/10.1158/1078-0432.CCR-09-0238; PMID: 20371674
- Jathal MK, Chen L, Mudryj M, Ghosh PM. Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block. Immunol Endocr Metab Agents Med Chem 2011; 11:131 - 49; http://dx.doi.org/10.2174/187152211795495643; PMID: 21603064
- Bluemn EG, Nelson PS. The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol 2012; 24:251 - 7; http://dx.doi.org/10.1097/CCO.0b013e32835105b3; PMID: 22327838
- Griffith CC, Seethala RR, Luvison A, Miller M, Chiosea SI. PIK3CA mutations and PTEN loss in salivary duct carcinomas. Am J Surg Pathol 2013; 37:1201 - 7; http://dx.doi.org/10.1097/PAS.0b013e3182880d5a; PMID: 23851329
- Perrone F, Suardi S, Pastore E, Casieri P, Orsenigo M, Caramuta S, Dagrada G, Losa M, Licitra L, Bossi P, et al. Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res 2006; 12:6643 - 51; http://dx.doi.org/10.1158/1078-0432.CCR-06-1759; PMID: 17121883
- Licitra L, Perrone F, Bossi P, et al. How High-Risk Human Papillomavirus affects prognosis of patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006; 24:5630 - 6; http://dx.doi.org/10.1200/JCO.2005.04.6136; PMID: 17179101
- Perrone F, Da Riva L, Orsenigo M, Losa M, Jocollè G, Millefanti C, Pastore E, Gronchi A, Pierotti MA, Pilotti S. PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor. Neuro Oncol 2009; 11:725 - 36; http://dx.doi.org/10.1215/15228517-2009-003; PMID: 19246520